LifeVantage Corporation (FRA:L2T1)
Germany · Delayed Price · Currency is EUR | Market Cap | 67.80M -32.5% |
| Revenue (ttm) | 159.82M -20.1% |
| Net Income | 4.44M -48.3% |
| EPS | 0.35 -46.7% |
| Shares Out | n/a |
| PE Ratio | 15.12 |
| Forward PE | 18.58 |
| Dividend | 0.16 (3.22%) |
| Ex-Dividend Date | Sep 1, 2026 |
| Volume | 276 |
| Open | 5.05 |
| Previous Close | 5.00 |
| Day's Range | 5.05 - 5.05 |
| 52-Week Range | 3.20 - 10.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About LifeVantage
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye a... [Read more]
Financial Performance
In fiscal year 2026, LifeVantage's revenue was $182.59 million, a decrease of -20.10% compared to the previous year's $228.53 million. Earnings were $5.07 million, a decrease of -48.27%.
Financial numbers in USD Financial StatementsNews
LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SALT LAKE CITY, Oct. 12, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”) today announced that its Board of Directors granted inducement awards to Terre...
LifeVantage Transcript: Water Tower Research Virtual Insights Conference
Leadership outlined a turnaround plan focused on brand differentiation, digital transformation, and operational efficiency. Growth will target improved messaging, technology investments, and international expansion in Japan and Mexico, while maintaining strong margins and shareholder returns.
LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026
SALT LAKE CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cell...
LifeVantage Proxy statement: Proxy filing
LifeVantage filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
LifeVantage Proxy statement: Proxy filing
LifeVantage filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
LifeVantage price target raised to $6 from $5 at Lake Street
Lake Street analyst Ryan Meyers raised the firm’s price target on LifeVantage (LFVN) to $6 from $5 and keeps a Hold rating on the shares following Q4 results the firm…
LifeVantage Earnings Call Transcript: Q4 2026
Q4 revenue declined 23.1% year-over-year to $42.4M, with gross margin at 78% and net income at $1.3M. Management is focused on brand building, digital upgrades, and operational improvements, with no formal FY27 guidance due to leadership transition.
LifeVantage Annual report: Q4 2026
LifeVantage has published its Q4 2026 annual report on August 27, 2026.
LifeVantage Earnings release: Q4 2026
LifeVantage released its Q4 2026 earnings on August 27, 2026, summarizing the period's financial results.
LifeVantage reports Q4 adjusted EPS 11c, consensus 13c
Reports Q4 revenue $42.38M, consensus $43.98M. “It’s a privilege to lead LifeVantage (LFVN) at this stage of its journey and my conviction about this Company is stronger today than when…
LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellu...
LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, Aug. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellul...
Security National Financial appoints Alissa Neufeld as CLO
Security National Financial Corporation (SNFCA) announced that Alissa Neufeld has joined the Company as Chief Legal Officer. Neufeld joins Security National from LifeVantage Corporation (LFVN), where ...
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2026 Results on August 27, 2026
SALT LAKE CITY, Aug. 13, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellula...
LifeVantage Welcomes Terrence Moorehead as Chief Executive Officer
SALT LAKE CITY, Aug. 05, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate opti...
Lifevantage trading halted, volatility trading pause
09:30 EDT Lifevantage (LFVN) trading halted, volatility trading pause
LifeVantage Transcript: WTR Insights Conference: Powered by The Small Cap Showcase
Leadership transition brings new international expertise, with growth focused on expanding beyond North America. Product innovation continues, but core offerings remain central as the company leverages scientific validation and maintains strong financial discipline, including share buybacks and a recent acquisition.
LifeVantage Slides: Investor presentation
LifeVantage has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
LifeVantage downgraded to Hold from Buy at Lake Street
Lake Street downgraded LifeVantage (LFVN) to Hold from Buy with a $5 price target Q3 results came in below expectations and while management maintained its prior FY26 guidance framework, it…
LifeVantage reports Q3 EPS 11c, consensus 16c
Reports Q3 revenue $43.72M, consensus $47.77M. “Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System were only partially offset by the addition of…
LifeVantage backs FY26 EPS view 60c-80c, consensus 67c
Backs FY26 revenue view $185M-$200M, consensus $192.75M. Backs FY26 adjusted EBITDA view $15M-$19M. The company said, “The Company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnin...
LifeVantage Earnings Call Transcript: Q3 2026
Q3 revenue fell 25.2% year-over-year due to lower MindBody GLP-1 sales, with adjusted EBITDA and net income also declining. Americas saw a notable drop in consultant count, but the company remains debt-free, increased its dividend, and expects full-year results near the low end of guidance.
LifeVantage Quarterly report: Q3 2026
LifeVantage has published its Q3 2026 quarterly earnings report on May 6, 2026.
LifeVantage Earnings release: Q3 2026
LifeVantage released its Q3 2026 earnings on May 6, 2026, summarizing the period's financial results.